Several phase II and III studies including an mTOR inhibitor have been completed in patients with advanced hormone receptor (HR)+ breast cancer, and so far three major randomized trials have reported consistent data in efficacy [33–35] (Table 1). Here, MTOR is linked to breast carcinoma.